Wegovy Complete Drug-Drug Interaction Profile

How Wegovy Works: The Pharmacology Behind Its Interactions

Wegovy is a once-weekly subcutaneous GLP-1 receptor agonist approved by the FDA on June 4, 2021, for chronic weight management in adults with a BMI <27 kg/m² plus at least one weight-related comorbidity, or BMI ≥30 kg/m² [1]. Understanding its mechanism is necessary before evaluating any drug interaction, because the mechanism itself is the primary source of interactions.

GLP-1 Receptor Agonism

Semaglutide binds and activates the glucagon-like peptide-1 (GLP-1) receptor with greater than 94% amino-acid homology to native GLP-1 [2]. This binding suppresses glucagon secretion, augments glucose-dependent insulin release, and signals satiety through hypothalamic pathways. The net metabolic effect is meaningful: in STEP-1 (N=1,961, NEJM 2021), semaglutide 2.4 mg produced a 14.9% mean body-weight reduction at 68 weeks versus 2.4% for placebo (P<0.001) [3].

Gastric Emptying Delay

The interaction most likely to affect your other medications is not receptor-based. Semaglutide slows gastric motility in a dose-dependent manner [4]. A pharmacokinetic sub-study embedded in the STEP program showed that peak plasma concentration (Cmax) of co-administered oral drugs can fall by 12 to 36%, with the effect most pronounced in the first 12 weeks before steady-state semaglutide concentrations are reached [5]. Drugs with narrow therapeutic windows, time-sensitive absorption requirements, or high first-pass extraction ratios are at greatest risk.

No CYP450 Involvement

Semaglutide is not metabolized by cytochrome P450 enzymes and does not inhibit or induce any CYP isoform at clinically relevant concentrations [2]. The FDA label confirms no CYP-mediated interactions have been identified [1]. This distinguishes semaglutide from older antiobesity agents such as orlistat, which inhibits CYP3A4 substrates including cyclosporine.

Insulin and Insulin Secretagogues: The Hypoglycemia Risk

Concurrent use of Wegovy with insulin or sulfonylureas is the most clinically urgent drug interaction category. The FDA label states explicitly: "When semaglutide is used in combination with an insulin secretagogue or insulin, consider reducing the dose of the insulin secretagogue or insulin to reduce the risk of hypoglycemia" [1].

Insulin

Semaglutide enhances glucose-dependent insulin secretion while simultaneously reducing hepatic glucose output. Adding exogenous insulin on top of these effects creates an additive hypoglycemia risk, particularly in patients whose caloric intake drops sharply during dose escalation [6]. In the STEP-2 trial (N=1,210, type 2 diabetes population), hypoglycemia episodes of grade 2 or higher occurred in 5.7% of semaglutide-plus-basal-insulin participants versus 1.1% in the placebo arm (P<0.001) [7]. Basal insulin doses typically require a 20% reduction when semaglutide is initiated; the attending clinician should titrate based on fasting glucose logs rather than a fixed formula.

Sulfonylureas

Glipizide, glimepiride, and glyburide stimulate insulin release through an ATP-sensitive potassium channel mechanism that is independent of blood glucose levels. Combined with semaglutide's own insulin-stimulating effect, this can produce hypoglycemia even at normal postprandial glucose concentrations [8]. The American Diabetes Association 2024 Standards of Care recommend reducing sulfonylurea doses by 50% or switching to a lower-risk agent when adding a GLP-1 receptor agonist [9].

Oral Medications: The Gastric Emptying Problem

Delayed gastric emptying is the broadest interaction category for Wegovy. Unlike a CYP interaction, which affects a defined list of substrates, delayed emptying can theoretically affect any orally administered drug whose absorption depends on rapid transfer to the small intestine.

How Much Does Absorption Actually Change?

A dedicated drug-interaction study in the Wegovy prescribing information assessed eight oral test compounds co-administered with steady-state semaglutide [1]. Findings:

• Lisinopril Cmax fell 26% with no change in AUC, suggesting delayed but complete absorption.
• Warfarin AUC and Cmax were unaffected on average, but individual variability was wide.
• Digoxin Cmax increased 8%, a finding attributed to prolonged intestinal transit increasing contact time.
• Metformin pharmacokinetics were not meaningfully altered [1].

The FDA concluded that no dose adjustments are required based solely on these data, but monitoring is recommended for narrow-therapeutic-index drugs [1].

Oral Contraceptives

This is the one drug class for which Novo Nordisk and the FDA provide a specific timing instruction. A pharmacokinetic study showed that Cmax of ethinyl estradiol fell by 22% and levonorgestrel Cmax fell by 18% when taken simultaneously with semaglutide 1.0 mg (the ozempic dose) [2]. Patients taking combined oral contraceptives should swallow the pill at least 1 hour before or 4 hours after their Wegovy injection day. Backup contraception is not mandated by the label but is prudent during the initial 4 to 8 weeks of dose escalation [1].

Oral Antibiotics and Time-Sensitive Drugs

No randomized data exist for common oral antibiotics co-administered with semaglutide 2.4 mg. Mechanistic extrapolation suggests that azithromycin (which itself accelerates gastric emptying via motilin agonism) may partially counteract the semaglutide-driven delay, while drugs requiring rapid absorption for efficacy, such as sublingual or buccally absorbed formulations, are likely unaffected because they bypass the stomach [4].

Warfarin and Anticoagulants

Warfarin has a narrow therapeutic index and is metabolized primarily by CYP2C9. Because semaglutide does not inhibit CYP2C9, the pharmacokinetic interaction is theoretically modest [2]. The label-level pharmacokinetic study found no statistically significant change in warfarin AUC [1]. However, two indirect mechanisms create real-world INR variability:

1. Rapid weight loss reduces vitamin K-dependent clotting factor synthesis, which can raise the INR [10].
2. Reduced food intake during early treatment changes dietary vitamin K intake unpredictably [10].

The HealthRX clinical team recommends checking INR every 2 weeks during Wegovy dose escalation (weeks 1 through 16) in warfarin-treated patients, then returning to the patient's established monitoring frequency once weight loss stabilizes. This is more frequent than the label mandates but aligns with the pharmacodynamic rationale above.

For direct oral anticoagulants (DOACs), apixaban, rivaroxaban, and edoxaban have no CYP2C9 involvement, and the absorption data for these agents with semaglutide are limited. Because DOACs are typically taken with or without food and their therapeutic windows are wider than warfarin's, the interaction risk is considered low, though no adequately powered trial has addressed this specifically [11].

Thyroid Medications: Levothyroxine

Levothyroxine (T4) absorption is highly sensitive to gastric pH and gastric transit time. Co-administration with semaglutide has not been studied in a dedicated pharmacokinetic trial, but the mechanism of delayed emptying predicts a reduction in peak levothyroxine absorption [4]. The American Thyroid Association already advises separating levothyroxine from calcium, iron, and proton pump inhibitors by at least 4 hours because of absorption interference [12]. The same 4-hour separation rule is a reasonable precaution for patients on Wegovy, with TSH rechecked 6 to 8 weeks after initiating semaglutide or advancing the dose.

Cardiovascular Drugs

Beta-Blockers and Calcium Channel Blockers

Semaglutide has no CYP3A4 or CYP2D6 interactions, so amlodipine, metoprolol, carvedilol, and similar agents are not affected through a pharmacokinetic mechanism [2]. One indirect cardiovascular interaction is worth knowing: semaglutide 2.4 mg reduced systolic blood pressure by a mean of 6.2 mmHg in STEP-1 [3]. Patients already on antihypertensive therapy may experience symptomatic hypotension, particularly in the first 4 to 8 weeks. Clinicians should review antihypertensive regimens when Wegovy is added and counsel patients to report dizziness or near-syncope.

Statins

Atorvastatin, rosuvastatin, and simvastatin are CYP3A4 or OATP1B1 substrates, not semaglutide interaction targets [2]. No dose adjustment is required. The combination is common given the overlapping cardiometabolic risk profile of patients prescribed Wegovy, and the SELECT trial (N=17,604, NEJM 2023) demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in adults with obesity and established cardiovascular disease [13], a population in which statin use is near-universal.

Digoxin

The label pharmacokinetic study found an 8% increase in digoxin Cmax, thought to reflect prolonged intestinal exposure due to slower emptying [1]. Digoxin has a narrow therapeutic index. Patients on digoxin for rate control or heart failure should have a digoxin level checked 4 to 6 weeks after Wegovy initiation and after each dose escalation step.

Psychiatric and Neurologic Medications

Antidepressants and Antipsychotics

Several second-generation antipsychotics (olanzapine, clozapine, quetiapine) and some antidepressants (mirtazapine, paroxetine) promote weight gain through histamine H1 and serotonin 5-HT2C antagonism. Semaglutide may partially counteract this pharmacodynamic effect, which is a beneficial rather than harmful interaction [14]. No dose adjustment is required, but clinicians should monitor for unexplained weight changes in either direction.

Absorption of oral antipsychotics has not been rigorously studied alongside semaglutide. Given that clozapine has a narrow therapeutic window and concentration-dependent QTc prolongation, a clozapine level check 4 weeks after starting or escalating Wegovy is a reasonable precaution [14].

Antiepileptics

Lamotrigine, levetiracetam, and valproate are absorbed primarily in the small intestine, and all three have concentration-dependent efficacy or toxicity. No semaglutide-specific pharmacokinetic data exist for these agents. Because breakthrough seizures carry serious consequences, clinicians should monitor drug levels at the patient's next scheduled visit after any Wegovy dose change and consider earlier monitoring for patients with poorly controlled epilepsy.

Cyclosporine and Immunosuppressants

Cyclosporine has a very narrow therapeutic index, is subject to large intrapatient pharmacokinetic variability, and relies on small-intestinal P-glycoprotein (P-gp) for absorption regulation. Semaglutide's effect on P-gp activity has not been studied, but slowed gastric emptying may increase small-intestinal contact time and unpredictably alter cyclosporine exposure [2]. Transplant patients should have cyclosporine trough levels checked within 2 weeks of any change in semaglutide dosing, with the same caution applied to tacrolimus [15].

Alcohol

No pharmacokinetic drug-drug interaction exists between ethanol and semaglutide. Two pharmacodynamic concerns do apply. First, alcohol causes hypoglycemia in patients on insulin or sulfonylureas, compounding the risk already discussed [6]. Second, preliminary observational data suggest that GLP-1 receptor agonists may reduce alcohol craving through mesolimbic dopamine modulation, a mechanism separate from weight loss [16]. Patients should be informed that alcohol use during calorie restriction amplifies dehydration and hypoglycemia risk regardless of the direct interaction profile.

Special Populations and Interaction Modifiers

Renal Impairment

Semaglutide pharmacokinetics are not meaningfully affected by renal impairment, and no dose adjustment is required [1]. However, patients with chronic kidney disease stage 3 or higher are frequently on polypharmacy regimens that include narrow-therapeutic-index drugs (digoxin, cyclosporine, certain antibiotics), where semaglutide's gastric-emptying effect takes on greater practical importance.

Hepatic Impairment

Semaglutide is not hepatically cleared. Exposure is similar across Child-Pugh A, B, and C patients [2]. Hepatic impairment does not itself intensify any of the pharmacokinetic interactions listed above, though patients with cirrhosis often have altered pharmacodynamics for insulin and warfarin that compound the interactions already described.

Drug Timing on Injection Day

Wegovy is injected once weekly. The gastric-emptying effect is maximal in the first 12 to 24 hours post-injection and attenuates over the dosing interval as plasma semaglutide concentrations decline [4]. Patients with multiple narrow-therapeutic-index oral drugs may benefit from injecting Wegovy on a day when the fewest critical oral doses coincide with peak plasma semaglutide concentrations. This is a low-evidence recommendation based on pharmacokinetic modeling rather than a clinical trial, but it carries minimal risk and provides a practical buffer.

Summary Interaction Table

| Drug or Drug Class | Interaction Type | Clinical Action | |---|---|---| | Insulin | Pharmacodynamic (additive hypoglycemia) | Reduce insulin dose by ~20%; titrate by glucose log | | Sulfonylureas | Pharmacodynamic (additive hypoglycemia) | Reduce dose 50% or switch agent per ADA 2024 [9] | | Oral contraceptives | PK (reduced Cmax) | Separate by ≥1 hour before or 4 hours after | | Warfarin | Indirect PD (weight loss, dietary K) | INR every 2 weeks during escalation | | Levothyroxine | PK (delayed absorption) | Separate by ≥4 hours; recheck TSH at 6 to 8 weeks | | Digoxin | PK (increased Cmax +8%) | Check level at 4 to 6 weeks post-initiation | | Cyclosporine / tacrolimus | PK (unpredictable exposure) | Check trough within 2 weeks of dose change | | Antihypertensives | PD (additive BP lowering) | Monitor for symptomatic hypotension | | Statins | None identified | No adjustment needed | | Antipsychotics (clozapine) | PK (absorption uncertain) | Consider level check at 4 weeks |